SLS
- SELLAS Life Sciences Group, Inc.
()
Overview
Company Summary
SELLAS Life Sciences Group, Inc. is a biopharmaceutical company that is primarily focused on the development of innovative immunotherapies for the treatment of various types of cancers. SELLAS specializes in developing therapies that stimulate the body's own immune system to target and eliminate cancer cells.
The company's primary product candidate is galinpepimut-S, a potential cancer immunotherapy. Galinpepimut-S is being developed for the treatment of multiple types of cancers, including acute myeloid leukemia (AML) and multiple myeloma (MM). It is designed to target specific cancer antigens present on the surface of tumors, stimulating the body's immune response to attack and eliminate these cancer cells.
SELLAS also focuses on developing a range of other immunotherapeutic products for the treatment of different types of cancers and other diseases. The company continuously explores new technologies and approaches to improve cancer treatment outcomes and enhance patients' lives.
In addition to its drug development initiatives, SELLAS actively engages in strategic collaborations and partnerships with other biopharmaceutical companies, academic institutions, and research organizations. These collaborations aim to leverage resources, expertise, and scientific advancements to accelerate the development and commercialization of innovative cancer immunotherapies.
Overall, SELLAS Life Sciences Group, Inc. is committed to advancing the field of immunotherapy by developing novel treatment options that have the potential to significantly impact the lives of cancer patients.